Navigating the Complex Landscape of ADC Quality Control: From Critical Quality Attributes (CQAs) to Clinical Success

Introduction

Antibody-drug Conjugates (ADCs) represent a transformative class of anti-cancer therapeutics. By synergizing the "targeted delivery" of antibodies with the "potent cytotoxicity" of small-molecule payloads, ADCs possess a unique multicomponent architecture—comprising the antibody, linker, and payload—that inherently elevates the complexity of physicochemical characterization and quality control (QC).

ADC quality directly dictates clinical efficacy, patient safety, and batch-to-batch consistency—defects in any component may trigger off-target toxicity or diminished anti-tumor activity. Thus, targeted detection of Critical Quality Attributes (CQAs) serves as a pivotal cornerstone throughout the drug’s R&D, production, and commercialization lifecycle.

Key Takeaways

• Structural Complexity: Managing the unique tripartite architecture beyond standard mAb QC frameworks.

• Heterogeneity Control: Prioritizing Drug-Antibody Ratio (DAR) distribution and conjugation stability for batch consistency.

• Safety Thresholds: Minimizing off-target toxicity via stringent free-payload and linker-stability monitoring.

• Functional Success: Integrating internalization kinetics and PK/ADME profiling for clinical translation.

Part 1: Structural Integrity and Conjugation Quality Control

This part focuses on the "structural foundation" quality control of ADCs—analyzing three categories of CQAs (antibody-related, linker-payload-related, and conjugation-related). It clarifies their key roles in ensuring targeting specificity and cytotoxic potency, alongside core detection methods.

Section I. Antibody-Related Quality Attributes and Detection Methods

Antibodies serve as the "targeting moiety" of ADCs. Their structure and purity directly govern target recognition precision. These quality attributes constitute the foundation of ADC quality control, extending beyond the established QC framework for standard monoclonal antibodies.

(I) Attributes Related to Antibody Structural Integrity

Significance: Structural integrity is the fundamental prerequisite for target engagement of ADCs. The primary structure is the cornerstone of specificity and safety; defects can result in compromised affinity or immunogenicity. Glycosylation, a critical post-translational modification (PTM), modulates key effector functions (e.g., ADCC) and pharmacokinetics (half-life); abnormal modifications can trigger aggregation or immunogenicity issues. Higher-Order Structure (HOS) is critical to preserving the 3D conformation required for receptor binding; misfolding inevitably leads to aggregation or potency loss.

Detection Methods:

(II) Control of Antibody-Related Impurities

Antibody-related impurities are key factors affecting ADC purity and safety, categorized into product-related impurities (aggregates/fragments resulting from antibody degradation or aggregation) and process-related impurities (e.g., Host Cell Proteins (HCP) and host cell DNA (hcDNA)), both of which can directly compromise efficacy and increase immunogenicity risks.

Significance: Aggregates, one of the most critical product-related impurities, expose hydrophobic groups that easily induce immunogenicity and reduce efficacy. Fragments such as Fab and Fc reduce the content of active ingredients due to their incomplete structure; the ratio of fragments to aggregates is key to batch consistency. Residual HCPs may trigger immune responses or interfere with stability, while DNA residuals pose potential carcinogenic risks and require strict content control.

Detection Methods:

Section II. Linker-Payload-Related Quality Attributes and Detection Methods

Linkers and cytotoxic payloads form the " therapeutic warhead"(or drug-linker complex) of ADCs. Their quality directly determines the therapeutic index—ensuring payload activity while avoiding premature dissociation-induced off-target toxicity. Relevant quality attributes are unique to ADC quality control, distinguishing ADCs from traditional monoclonal antibodies.

Significance: Plasma stability of linkers is critical for controlling ADC off-target toxicity. Ideal linkers should remain stable in the bloodstream to prevent premature payload release into normal tissues. Instability can lead to premature cleavage, causing systemic toxicities (e.g., myelosuppression) and a narrowed therapeutic window. Free payloads, process-related impurities from incomplete conjugation during production, are highly cytotoxic—residual free payloads drastically increase off-target toxicity and must be controlled to extremely low limits (≤1%), making them a top priority for ADC safety control.

Detection Methods:

Fig1. Case studies demonstrate that ADC DS-8201 can be efficiently cleaved by Cathepsin B from ACROBiosystems. The high enzymatic activity ensures the predictability of payload release kinetics, which is critical for in vitro efficacy validation.

Section III. Conjugation-Related Quality Attributes and Detection Methods

Conjugation technology represents a primary technical barrier in ADCs development. Conjugation-related quality attributes directly determine ADC homogeneity, efficacy consistency, and safety—among which the DAR is the pivotal CQA of the entire ADC quality control system.

(I) Drug-Antibody Ratio (DAR)

Significance: DAR refers to the number of payloads conjugated per antibody molecule. Average DAR directly dictates the overall potency of ADCs—suboptimal loading compromises efficacy, while excessive loading precipitates protein aggregation and off-target toxicity. DAR distribution reflects product homogeneity, requiring strict control of the proportion of each DAR component and batch consistency.

Detection Methods:

(II) Conjugation Site Specificity

Significance: Conjugation site specificity is a core quality indicator for site-specific ADCs. Site-specific conjugation achieves payload attachment at antibody-specific sites via genetic engineering, significantly improving DAR homogeneity. Insufficient site specificity leads to unintended conjugation sites, resulting in broadened DAR distribution, reduced activity, or increased toxicity. For random conjugation ADCs, while absolute site-specificity is not required, consistency of site distribution profile must be controlled.

Detection Methods: LC-MS/MS is the core technology. ADCs are enzymatically hydrolyzed into peptides (e.g., trypsin, pepsin); peptides are separated by RP-HPLC; MS/MS measures peptide molecular weights and amino acid sequences, comparing pre- and post-conjugation molecular weight changes to confirm conjugation sites and efficiency. This method achieves localization to specific amino acid sites with a quantitative error of ≤5% for conjugation efficiency. It is versatile for both site-specific and random conjugation, simultaneously obtaining site accuracy and efficiency data:

Fig2. Quality characterization of ADC substance. Case studies show that the ADC prepared using the ADC Conjugation Kit (MMAE, DAR4) （Cat. No. ADC-P013）from ACROBiosystems exhibit high purity and controlled homogeneity. Analysis by HIC and SEC-HPLC confirms an average DAR of 4.0±0.5 and the purity of the ADC is greater than 95%.

Fig3. The DAR (3.82) was calculated from the weighted average of the deconvoluted MS peak areas using LC-MS/MS. The results showed the deconvoluted mass spectra of light chains and heavy chains, and the increase in molecular weight caused by the conjugated payload (1316±3 Da). The heterogeneity in N-glycosylation of heavy chain adds to the complexity of the mass spectrum.

ADC quality control is a systematic endeavor. While Part 1 established the structural foundation—covering antibody precision, linker stability, and conjugation homogeneity—these attributes must ultimately be validated through biological function. The following sections in Part 2 address the pivotal questions linking structure to clinical success: Can the ADC precisely bind, efficiently internalize, and effectively kill? By focusing on this " functional validation" phase, we define the final quality defense line for ADCs from R&D to clinical application.

Part 2: Bioactivity Assessment and Clinical Translation Verification

Following the structural-level quality control of ADCs in Part 1, this part focuses on the functional evaluation of ADC—binding, internalization, and cytotoxicity, pharmacokinetic，and immunogenicity. These attributes are directly related to clinical efficacy and safety, requiring dual verification through in vitro and in vivo experiments, and serve as key checkpoints for ADCs transitioning from research and development to clinical applications.

(I) Antigen-Binding Activity

Significance: Antigen-binding affinity is the prerequisite for validating the "targeted delivery" mechanism. Only precise binding ensures the enrichment of the cytotoxic payload within the tumor microenvironment, avoiding off-target effects. It is also necessary to strictly verify binding specificity to exclude non-specific binding to normal cells. Additionally, the retention of binding activity post-conjugation must be monitored to prevent conformational damage to the antibody.

Detection Methods: A multi-dimensional detection scheme combining "qualitative + quantitative + specificity" is adopted.

Fig4. Antigen-binding affinity validation via SPR. Captured Trop2 antibody on CM5 chip via anti-mouse antibodies surface can bind ACROBiosystems’ Human TROP-2, His Tag (Cat. No. TR2-H5223) with an affinity constant of 5.98 nM as determined in a SPR assay (Biacore T200).

(II) ADC Internalization Efficiency

Significance: Efficient internalization (receptor-mediated endocytosis) is a prerequisite for intracellular payload release. This stage validates whether candidate molecules exhibit sufficient internalization rates. Molecules with poor internalization kinetics may fail to deliver therapeutic concentrations of the payload even with strong binding activity. This attribute is often combined with binding data to select candidates with "high binding + high internalization."

Detection Methods:

Fig5. Fluorescence Imaging of Antibody Internalization. SK-BR-3 cells were treated with CellLights Lysosome GFP (green) for 16 hours followed by treatment with Anti-Her2 Abs-Internalization Detection Reagent conjugate and IgG1 Isotype-Internalization Detection Reagent conjugate separately for 16 hours (red), then stained with NucBlue Live ReadyProbes(blue) for 20 minutes and imaged on the EVOS M7000. A. Antibody Internalization Detection Reagent (Cat.No.IGG-PZF2001) from ACROBiosystems. B. IgG1 Isotype-Internalization Detection Reagent conjugate. C. Anti-Her2 Abs-Internalization Detection Reagent conjugate. D. Anti-Her2 Abs-Internalization Detection Reagent conjugate(Z-stacking).

(III) Target Cell Cytotoxicity (Potency)

Significance: Target cell cytotoxicity reflects the potency of the payload delivery system. This attribute requires simultaneous verification of "targeted killing specificity" and "cytotoxic potency"—i.e., eliminating antigen-positive tumor cells with no significant toxicity to negative cells.

Detection Methods: In vitro cell proliferation inhibition assays serve as the core, supplemented by apoptosis detection. Common methods include metabolic activity-based assays such as CCK-8, MTT, or the quantification of cellular biomarkers (e.g., intracellular ATP, lactate dehydrogenase (LDH) release, NADH, or proteases activity).

The cytotoxic activity of ADCs on target-positive cells is quantified by measuring metabolic shifts, followed by the calculation of the half-maximal inhibitory concentration (IC₅₀). Crucially, a lower IC₅₀ value correlates with superior killing potency. To validate the therapeutic window, cytotoxicity against antigen-negative cells must be assessed in parallel. For internalizing ADCs, fluorescence tracking is employed to visualize intracellular trafficking and payload release kinetics, providing mechanistic insights into the ADC's mode of action (MoA).

(IV) Pharmacokinetic (PK) Attributes

Significance: Pharmacokinetic profiling characterizes the comprehensive absorption, distribution, metabolism, and excretion (ADME) profile of ADCs in vivo. As a critical bridge linking in vitro structural characterization with in vivo pharmacological performance, PK data directly inform clinical dose escalation, dosing intervals, and the duration of therapeutic effect. Furthermore, PK parameters serve as high-level indicators for evaluating batch-to-batch consistency.

Critical parameters include plasma clearance (CL), terminal half-life (t₁/₂), and volume of distribution (V_d), all of which are inextricably linked to structural attributes such as DAR, antibody glycosylation (e.g., fucosylation levels), and linker stability. For example, species with high DAR or excessive drug loading are often prone to accelerated clearance by the reticuloendothelial system (RES), resulting in truncated systemic exposure.

Detection Methods: Overall, experiments are conducted using in vivo animal models (e.g., mice, rats, non-human primates) combined with quantitative analysis of biological samples, complying with FDA/NMPA preclinical pharmacokinetic research guidelines throughout. By integrating quantitative bioanalysis of various analytes (e.g., total antibody, conjugated antibody, and free payload), researchers can accurately delineate the ADC's metabolic fate to meet stringent regulatory filing requirements.

Fig6. Comparative analysis of three methods for the total antibody content of Trastuzumab-MMAE. To optimize PK assay performance, three formats were evaluated using ACROBiosystems’ high-affinity reagents: A. A generic sandwich ELISA method, in which ACRO’s anti-human IgG polyclonal antibodies were used for both capture and detection; B. A hybrid method using ACROBiosystems’s anti-human IgG monoclonal antibody for capture and polyclonal antibody for detection; C. An indirect antigen-capture assay, in which the capturing reagent was human HER2 (from ACROBiosystems) and the detecting reagent was an anti-human IgG antibody.

Fig7. The results of two different quantitative Trastuzumab MMAE specific antibody. A. Fc-based detection: Indirect ELISA using anti-MMAE antibody (ACROBiosystems) for capture. B. Streptavidin-based detection: Sandwich ELISA using anti-MMAE capture (ACROBiosystems) and a Biotin-SA HRP system.

Fig8. Sensitivity validation for Intact ADC assay. Immobilized Anti-idiotype Antibody (Mouse IgG1, ACROBiosystems) was used to capture ADC drug candidates, followed by the addition of Biotinylated Mouse Anti-MMAE Antibody (MALS verified, Cat. No. MME-M5252, ACROBiosystems). Detection was performed using HRP-conjugated streptavidin with a measured sensitivity of 0.69 ng/mL.

(V) Immunogenicity Assessment

Significance: Anti-drug antibodies (ADA) are the host's immune responses to ADCs. Their presence directly affects the clinical efficacy and the patient's safety profile. Due to the ternary structure of ADCs ("antibody-linker-payload"), their immunogenicity risk is inherently more complex than that of conventional monoclonal antibodies (mAbs).

Specific risks include:

① Neutralizing ADA: These antibodies can bind to the paratope (antigen-binding site) or the payload moiety, directly precluding target engagement or hindering intracellular payload release, thereby nullifying therapeutic potency.

② Non-neutralizing ADA: While these do not directly interfere with functional domains, they can form immune complexes, accelerate systemic clearance and reduce drug exposure (AUC).

③ Safety risks: ADA may induce infusion-related reactions (IRRs), hypersensitivity, or severe organ damage (e.g., nephrotoxicity) mediated by immune complex deposition.

④ Neo-epitopes: Beyond the antibody scaffold, the payloads, linkers, and the neo-epitopes created at the conjugation sites can act as potent immunogens, inducing various ADAs such as anti-antibody, anti-payload, and anti-conjugation site antibodies.

Detection Methods: The industry-accepted three-step method ("screening - confirmation - neutralizing activity detection") complying with FDA/NMPA bioanalytical guidelines is adopted. Control settings are strengthened throughout to avoid false positives, ensuring that test results can support ADC quality control and clinical filing.

Conclusion

The ADC quality control system is anchored in the core goals of " precise targeting, potent cytotoxicity, and controllable safety".

The hierarchical progression of quality attributes ranges from the antibody-driven targeting foundation, linker-payload-mediated potency, and conjugation-driven homogeneity, to the overall biological attributes that verify final functional performance.

Notably, ADC quality control is not a “one-size-fits-all” paradigm. While regulatory mandates define clear thresholds for core indicators (e.g., DAR, residual free payload), subdivided CQAs (e.g., glycosylation profiles, aggregation limits) should be established through a Quality by Design (QbD) approach, tailored to the specific molecule, manufacturing process, and clinical objectives. As technologies such as site-specific conjugation and next-generation linkers continue to mature, the evaluation framework will evolve toward higher sensitivity and predictive accuracy, laying the groundwork for the successful clinical translation and safe application of ADCs.

Accelerate Your ADC Journey with ACROBiosystems Mastering ADC complexity requires precision tools. We provide the critical reagents and expert technical support needed to decode your drug’s quality attributes.

[Contact Us] Today to explore our full range of ADC solutions.